The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Dr Ivo Abraham: Biosimilar Pegfilgrastims vs Neulasta Onpro UtilizationJune 24th 2021
Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, talks about the role that the pandemic has played in the struggle between biosimilar pegfilgrastims and the on-body injector version of the reference product.
Xcenda Report Shows Biosimilar Competition Lowered Drug Prices of Reference Oncology BiologicsJune 23rd 2021
A report from Xcenda showed that biosimilars for 8 blockbuster reference biologics have successfully kept drug prices from increasing by an average of 56%, restoring the possibility that biosimilars could achieve significant discounts despite facing several barriers to uptake.
Dr Ivo Abraham on How Neulasta Onpro Is Impacting the Biosimilars SpaceJune 18th 2021
Ivo Abraham, PhD, RN, a professor in the Department of Pharmacy Practice at University of Arizona Health Sciences, talks about the results from his cost-efficiency studies and how Amgen’s Onpro pegfilgrastim device has affected cancer care and costs.
Dr Ivo Abraham Details the Current State of G-CSF Biosimilars in the USJune 11th 2021
Ivo Abraham, PhD, RN, a professor with the University of Arizona Health Sciences in the Department of Pharmacy Practice, discusses the current state of the granulocyte-colony stimulating factor (G-CSF) sector of the biosimilar market.
High-Concentration Adalimumab Biosimilar Yields Positive 1-Year DataJune 2nd 2021
Celltrion Healthcare’s high-concentration adalimumab biosimilar demonstrated comparable safety, efficacy, and immunogenicity profiles to the reference product for up to a year, providing further evidence supporting use of the product.
Dr Sonia Oskouei Differenciates Pharmacist Concerns From Physicians' Regarding BiosimilarsJune 1st 2021
Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, talks about the differences between provider and pharmacist concerns and whether health organizations giving more power to pharmacists causes conflict with physicians.
Dr Sonia Oskouei Discusses the Potential for the First Interchangeable BiosimilarMay 26th 2021
Sonia T. Oskouei, PharmD, BCMAS, DPLA, from Cardinal Health, explains the ramifications that interchangeability designations will have on biosimilars and when we might see the first interchangeable biosimilar in the United States.
Switches to Adalimumab Biosimilars Yielded Similar Outcomes to the Reference Product in IBDMay 21st 2021
After switching to 1 of 2 adalimumab biosimilars, patients with inflammatory bowel disease (IBD) experienced comparable clinical outcomes to the reference product after 6 months, according to a recent study.
Payer Preferences May Help Drive Biosimilar Uptake and Sizeable Savings in OncologyMay 14th 2021
A poster presentation highlighted the impact that payer preferences could have on biosimilar utilization and the potential savings that could be generated if payers decide to take advantage.
Alvotech Heats Up Patent Dispute Conflict by Suing AbbVie Over Humira BiosimilarMay 11th 2021
Under the lawsuit, Alvotech alleges that AbbVie is unlawfully taking advantage of patent laws and claims courts to prevent biosimilar competition rivaling its blockbuster drug, Humira, from entering the US market.
Dr. Ryan Haumschild Outlines Ways to Boost Physician Confidence in BiosimilarsDecember 1st 2020
Ryan Haumschild, PharmD, director of pharmacy at Emory Healthcare in Atlanta, Georgia, discussed results to the survey he conducted on biosimilar utilization and planned initiatives about how to increase physician confidence in biosimilars.